Antagonistic interaction of lacosamide with carbamazepine and valproate in the mouse tonic-clonic seizure model

• Autorzy: Kondrat-Wrobel M.W. , Zaluska K. , Walczak A. , Panasiuk-Poterek A.N. , Gut-Lepiech A. , Wroblewska-Luczka P. , Luszczki J.J.

Warianty tytułu

PL

Antagonistyczna interakcja lakozamidu z karbamazepiną i walproainianem w modelu drgawek toniczno-klonicznych u myszy

• Języki publikacji: EN

Abstrakty

EN

Background. It is estimated that approximately 1% of people worldwide suffer from epilepsy. Currently available antiepileptic drugs (AEDs) are able to control epileptic seizures in about 70% of cases. In the remaining patients (30%), the application of two or three AEDs in combination is necessary for effective seizure management. The goal of this work was to characterize the interaction of three AEDs: lacosamide (LCM), carbamazepine (CBZ) and valproate (VPA) at the fixed-ratio of 1:1:1 in the mouse tonic-clonic seizure model. Material and methods. Male albino Swiss mice, after receiving a combination of LCM, CBZ and VPA, were challenged with electric current to evoke tonic hind limb extension (seizure activity). Protection of the mice from tonic-clonic seizures was assessed by isobolographic analysis to determine the type of interaction occurring between these drugs. Results. Type I isobolographic analysis revealed that the combination of LCM, CBZ and VPA produced infra-additive (antagonistic) interaction in the mouse tonic-clonic seizure model. Conclusions. Since the three-drug mixture of LCM, CBZ a nd VPA exerted an antagonistic interaction in the tonic-clonic seizure test in mice, we would caution physicians against treating epilepsy patients with this unfavorable combination.

PL

Wprowadzenie. Szacuje się, że około 1% osób na całym świecie cierpi na padaczkę. Obecnie dostępne leki przeciwpadaczkowe pozwalają na opanowanie napadów padaczkowych w około 70% przypadków. U pozostałych pacjentów z padaczką (30%) konieczne jest zastosowanie dwóch lub trzech leków przeciwpadaczkowych w kombinacji. Celem pracy było scharakteryzowanie interakcji między trzema lekami przeciwpadaczkowymi: lakozamidem (LCM), karbamazepiną (CBZ) i walproinianem (VPA) w stałym stosunku dawek 1:1:1 w modelu drgawek toniczno-klonicznych u myszy. Materiał i metody. Samce myszy albino Swiss, po otrzymaniu kombinacji LCM, CBZ i VPA, poddano działaniu prądu elektrycznego, aby wywołać toniczny wyprost kończyn tylnych (aktywność drgawkową). Ochronę myszy przed napadami toniczno-klonicznymi oszacowano za pomocą analizy izobolograficznej, aby określić typ interakcji zachodzącej między tymi lekami. Wyniki. Analiza izobolograficzna typu I ujawniła, że kombinacja LCM, CBZ i VPA powodowała oddziaływanie infra-addytywne (antagonistyczne) w modelu drgawek toniczno-klonicznych u myszy. Wnioski. Ponieważ trójlekowa mieszanina LCM, CBZ i VPA wywierała antagonistyczną interakcję w teście napadów toniczno-klonicznych u myszy, specjalne ostrzeżenie jest konieczne dla lekarzy, aby nie leczyć pacjentów z padaczką tą niekorzystną kombinacją.

Słowa kluczowe

EN

antagonistic interaction; antiepileptic drug; lacosamide; carbamazepine; valproate; mouse; mice; seizure; three-drug combination

• Wydawca: -
• Czasopismo: Health Problems of Civilization
• Rocznik: 2019
• Tom: 13
• Numer: 1
• Opis fizyczny: p.92-98,fig.,ref.

Twórcy

autor

Kondrat-Wrobel M.W.

• Department of Pathophysiology, Medical University of Lublin, 20-090 Lublin, Poland

autor

Zaluska K.

• Department of Pathophysiology, Medical University of Lublin, 20-090 Lublin, Poland

autor

Walczak A.

• Department of Pathophysiology, Medical University of Lublin, 20-090 Lublin, Poland

autor

Panasiuk-Poterek A.N.

• Department of Pathophysiology, Medical University of Lublin, 20-090 Lublin, Poland

autor

Gut-Lepiech A.

• Department of Pathophysiology, Medical University of Lublin, 20-090 Lublin, Poland

autor

Wroblewska-Luczka P.

• Department of Pathophysiology, Medical University of Lublin, 20-090 Lublin, Poland

autor

Luszczki J.J.

• Department of Pathophysiology, Medical University of Lublin, 20-090 Lublin, Poland
• Isobolographic Analysis Laboratory, Institute of Rural Health, Lublin, Poland

Bibliografia

• 1. Sadr SS, Javanbakht J, Javidan AN, Ghaffarpour M, Khamse S, Naghshband Z. Descriptive epidemiology: prevalence, incidence, sociodemographic factors, socioeconomic domains, and quality of life of epilepsy: an update and systematic review. Arch Med Sci. 2018; 14: 717-724. https://doi.org/10.5114/aoms.2016.60377
• 2. Stephen LJ, Brodie MJ. Seizure freedom with more than one antiepileptic drug. Seizure. 2002; 11: 349-351. https://doi.org/10.1053/seiz.2002.0711
• 3. Stephen LJ, Forsyth M, Kelly K, Brodie MJ. Antiepileptic drug combinations – have newer agents altered clinical outcomes?. Epilepsy Res. 2012; 98: 194-198. https://doi.org/10.1016/j.eplepsyres.2011.09.008
• 4. Deckers CL, Czuczwar SJ, Hekster YA, Keyser A, Kubova H, Meinardi H, et al. Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed. Epilepsia. 2000; 41: 1364-1374. https://doi.org/10.1111/j.1528-1157.2000.tb00111.x
• 5. Blaszczyk B, Miziak B, Czuczwar P, Wierzchowska-Cioch E, Pluta R, Czuczwar SJ. A viewpoint on rational and irrational fixed-drug combinations. Exp Rev Clin Pharmacol. 2018; 11: 761-771. https://doi.org/10.1080/17512433.2018.1500895
• 6. Kondrat-Wrobel MW, Luszczki JJ. Interaction of three-drug combination of lacosamide, carbamazepine and phenobarbital in the mouse maximal electroshock-induced seizure model – an isobolographic analysis. Health Prob Civil. 2016; 10(1): 55-61. https://doi.org/10.5114/hpc.2016.58209
• 7. Kondrat-Wrobel MW, Luszczki JJ. Isobolographic additivity among lacosamide, lamotrigine and phenobarbital in the mouse tonic-clonic seizure model. Adv Clin Exp Med. 2018; 27: 881-886. https://doi.org/10.17219/acem/69132
• 8. Kondrat-Wrobel MW, Luszczki JJ. Additive interaction for three-drug combination of carbamazepine, lacosamide and lamotrigine against maximal electroshock-induced seizures – a type I isobolographic analysis. Eur J Clin Exp Med. 2017; 15: 303-309. https://doi.org/10.15584/ejcem.2017.4.1
• 9. Luszczki JJ. Isobolographic analysis of interaction for three-drug combination of carbamazepine, phenobarbital and topiramate in the mouse maximal electroshock-induced seizure model. Pharmacology. 2016; 97: 259-264. https://doi.org/10.1159/000444452
• 10. Makinen J, Rainesalo S, Raitanen J, Peltola J. The effect of newer antiepileptic drugs in combination therapy. Epilepsy Res. 2017; 132: 15-20. https://doi.org/10.1016/j.eplepsyres.2017.02.020
• 11. Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol. 2003; 2: 347-356. https://doi.org/10.1016/S1474-4422(03)00409-5
• 12. Luszczki JJ. Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions. Pharmacol Rep. 2009; 61: 197-216. https://doi.org/10.1016/S1734-1140(09)70024-6
• 13. Lukawski K, Andres-Mach M, Czuczwar M, Luszczki JJ, Kruszynski K, Czuczwar SJ. Mechanisms of epileptogenesis and preclinical approach to antiepileptogenic therapies. Pharmacol Rep. 2018; 70: 284-293. https://doi.org/10.1016/j.pharep.2017.07.012
• 14. Tallarida RJ. Drug combinations: tests and analysis with isoboles. Curr Protocol Pharmacol. 2016; 72: 11-19. https://doi.org/10.1002/0471141755.ph0919s72
• 15. Nevitt SJ, Marson AG, Weston J, Tudur Smith C. Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review. Cochrane Database Syst Rev. 2017; 2: Cd001911. https://doi.org/10.1002/14651858.CD001911.pub3
• 16. Nolan SJ, Marson AG, Weston J, Tudur Smith C. Phenytoin versus valproate monotherapy for partial onset seizures and generalised onset tonic-clonic seizures: an individual participant data review. Cochrane Database Syst Rev. 2016; 4: Cd001769. https://doi.org/10.1002/14651858.CD001769.pub3
• 17. Weston J, Shukralla A, McKay AJ, Marson AG. Lacosamide add-on therapy for partial epilepsy. Cochrane Database Syst Rev. 2015; 6: Cd008841. https://doi.org/10.1002/14651858.CD008841.pub2
• 18. Franco V, French JA, Perucca E. Challenges in the clinical development of new antiepileptic drugs. Pharmacol Res. 2016; 103: 95-104. https://doi.org/10.1016/j.phrs.2015.11.007
• 19. Kocharov SL, Panosyan HA, Marzeda P, Wroblewska-Luczka P, Kochman E, Wlaz A, et al. Anticonvulsant potency of 10 various p-isopropoxyphenylsuccinimide derivatives in the maximal electroshock-induced seizure threshold model in mice. Health Prob Civil. 2017; 11(3): 195-201. https://doi.org/10.5114/hpc.2017.70010
• 20. NRC. Guide for the care and use of laboratory animals. 8th edition. Washington (DC): National Academies Press; 2011.
• 21. Litchfield JT Jr, Wilcoxon F. A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther. 1949; 96: 99-113.
• 22. Luszczki JJ, Mazurkiewicz LP, Wroblewska-Luczka P, Wlaz A, Ossowska G, Szpringer M, et al. Combination of phenobarbital with phenytoin and pregabalin produces synergy in the mouse tonic-clonic seizure model: an isobolographic analysis. Epilepsy Res. 2018; 145: 116-122. https://doi.org/10.1016/j.eplepsyres.2018.06.003
• 23. Bourgeois BF. Anticonvulsant potency and neurotoxicity of valproate alone and in combination with carbamazepine or phenobarbital. Clin Neuropharmacol. 1988; 11: 348-359. https://doi.org/10.1097/00002826-198808000-00003
• 24. Shandra A, Shandra P, Kaschenko O, Matagne A, Stohr T. Synergism of lacosamide with established antiepileptic drugs in the 6-hz seizure model in mice. Epilepsia. 2013; 54: 1167-1175. https://doi.org/10.1111/epi.12237
• 25. Thomas EA, Petrou S. Network-specific mechanisms may explain the paradoxical effects of carbamazepine and phenytoin. Epilepsia. 2013; 54: 1195-1202. https://doi.org/10.1111/epi.12172
• 26. Tallarida RJ. The interaction index: a measure of drug synergism. Pain. 2002; 98: 163-168. https://doi.org/10.1016/S0304-3959(02)00041-6
• 27. Gennings C. Economical designs for detecting and characterizing departure from additivity in mixtures of many chemicals. Food Chem Toxicol. 1996; 34: 1053-1058. https://doi.org/10.1016/S0278-6915(97)00074-4
• 28. Luszczki JJ, Czuczwar SJ. Preclinical profile of combinations of some second-generation antiepileptic drugs: an isobolographic analysis. Epilepsia. 2004; 45: 895-907. https://doi.org/10.1111/j.0013-9580.2004.05104.x
• 29. Berenbaum MC. What is synergy?. Pharmacol Rev. 1989; 41: 93-141.
• 30. Luszczki JJ, Czuczwar M, Kis J, Krysa J, Pasztelan I, Swiader M, et al. Interactions of lamotrigine with topiramate and first-generation antiepileptic drugs in the maximal electroshock test in mice: an isobolographic analysis. Epilepsia. 2003; 44: 1003-1013. https://doi.org/10.1046/j.1528-1157.2003.10003.x, https://doi.org/10.1046/j.1528-1157.2003.32702.x
• 31. Besag FM, Berry DJ, Pool F, Newbery JE, Subel B. Carbamazepine toxicity with lamotrigine: pharmacokinetic or pharmacodynamic interaction?. Epilepsia. 1998; 39: 183-187. https://doi.org/10.1111/j.1528-1157.1998.tb01356.x
• 32. Riva R, Albani F, Contin M, Baruzzi A. Pharmacokinetic interactions between antiepileptic drugs. Clinical considerations. Clin Pharmacokin. 1996; 31: 470-493. https://doi.org/10.2165/00003088-199631060-00005

Identyfikatory

DOI

10.5114/hpc.2019.81105